|Home | About | Journals | Submit | Contact Us | Français|
Cellular senescence represents a tumor suppressive response to a variety of aberrant and oncogenic insults. We have previously described a transgenic mouse model of Cyclin D1-driven senescence in pineal cells that opposes tumor progression. We now attempted to define the molecular mechanisms leading to p53 activation in this model, and to identify effectors of Cyclin D1-induced senescence.
Senescence evolved over a period of weeks, with initial hyperproliferation followed by cell cycle arrest due to ROS production leading to activation of a DNA damage response and the p53 pathway. Interestingly, cell cycle exit was associated with repression of the Cyclin-dependent kinase Cdk2. This was followed days later by formation of heterochromatin foci correlating with RB protein hypophosphorylation. In the absence of the Cdk4-inhibitor p18Ink4c, cell cycle exit was delayed but most cells eventually showed a senescent phenotype. However, tumors later arose from this premalignant, largely senescent lesion. We found that the p53 pathway was intact in tumors arising in a p18Ink4c-/- background, indicating that the two genes represent distinct tumor suppressor pathways. Upon tumor progression, both p18Ink4c-/- and p53-/- tumors showed increased Cdk2 expression. Inhibition of Cdk2 in cultured pre-tumorigenic and tumor cells of both backgrounds resulted in decreased proliferation and evidence of senescence.
Our findings indicate that the p53 and the RB pathways play temporally distinct roles in senescence induction in Cyclin D1-expressing cells, and that Cdk2 inhibition plays a role in tumor suppression, and may be a useful therapeutic target.
Cellular senescence is a well-established tumor suppressor mechanism, activated in response to oncogenic signals, DNA damage, and telomere attrition among other pro-tumorigenic insults (reviewed in [1,2]). Mechanistic insight into oncogene-induced senescence has emerged over the past few years. While it is clear that both the p53 and the Rb tumor suppressors are involved [3-6], their relative importance seems to vary depending on the activating insult and cellular context [3,7-10]. Understanding the relative contributions of p53 and Rb to the induction and maintenance of senescence may have important implications, especially with development of targeted therapeutic agents.
Cyclin-dependent kinase 2 (Cdk2) was recently implicated in the senescence process, as Cdk2 loss was found to enhance senescence in Myc-induced tumors . In addition, it was shown that Cdk2-dependent phosphorylation of Myc was necessary to bypass Ras-induced senescence . This suggests that Cdk2 may act in senescence independently of its role in RB phosphorylation and cell cycle exit.
Here, we used a transgenic mouse model of premalignant Cyclin D1-driven pineal gland hyperplasia, to define the molecular mechanisms leading to p53 activation in response to Cyclin D1, and to identify effectors of Cyclin D1-induced senescence. The results shed light on the pattern of evolution of the senescence response in a premalignant lesion in vivo, and the differences in the contribution of the two major tumor suppressor pathways, p53 and RB. In addition, our findings suggest that Cdk2 inhibition may be a useful therapeutic approach, irrespective of the underlying genetic insult that led to senescence evasion.
Cyclin D1-induced senescencein vivooccurs over a time frame of several weeks: We used the Irbp-Cyclin D1 mouse in which the expression of Cyclin D1 in the pineal gland causes excessive proliferation that is limited by senescence. The net result is a hyperplastic but senescent pineal gland that does not progress into an invasive tumor unless either p53 or the Cdk4-inhibitor p18Ink4c is lost . We examined the temporal evolution of senescence and the contribution of the p53 and Rb tumor suppressor pathways to cell cycle exit in vivo. Histological studies of Cyclin D1-expressing pineal glands at various ages (post-natal day (P)10, P24, P35, and P49) showed that enhanced proliferation, measured by Ki67 immunostaining, was apparent at P10 but after this point it decreased such that essentially all cells had exited the cell cycle by P35 [Figure [Figure1A,1A, left panel, Quantitation in Figure Figure1B].1B]. Cessation of proliferation preceded the formation of senescence-associated heterochromatin foci (SAHF); in fact, there was an unexpectedly long, two-week delay from P35 to P49 before SAHF were apparent [Figure [Figure1A,1A, middle and right panels]. Because SAHF have been observed in only a few mouse models of senescence [14-16], but not in other murine cells like MEFs , and because constitutive centromeric heterochromatin may show intense DAPI staining mimicking SAHF in normal murine cells [18,19], we verified that these foci were indeed only seen in Cyclin D1-expressing cells and not the wild-type counterparts at P49 Additional file 1: Figure S1A]. We could not detect positive staining for senescence-associated beta galactosidase (SABG), another marker of senescence . However, we believe this must be a technical issue (detecting the enzyme activity necessitates freshly frozen tissue), because when the Cyclin D1-expressing pineal cells were grown in vitro, they showed features of senescence that included positive staining for SABG [see below, and Additional file 1: Figure S1B]. In addition, we evaluated the pineal cells for other known markers of senescence, such as Dec1, DcR2, and p15Ink4b . We found that, concomitant with cell cycle exit and SAHF formation, all three markers of senescence were increased at P49 [Figure [Figure1C].1C]. We conclude that Cyclin D1-induced senescence in the pineal cells occurs by P49, and that cell cycle exit in this setting occurs many days prior to expression of bona fide markers of senescence.
p53 activation occurs prior to cell cycle exit, and is mediated by a ROS-induced DNA damage response: To identify when p53 was engaged in tumor suppression, we evaluated cell lysates of pineal glands collected at different postnatal ages. We found that at P10, p53 protein expression was increased, as was its phosphorylation at Ser15/20 (a site phosphorylated by the DNA damage response) [Figure [Figure2A].2A]. The p53 target, p21Cip1, was also induced at that time-point [Figure [Figure2A].2A]. However, p53 activation did not persist once the cells had exited the cell cycle nor was it detectable at P49 when the cells displayed SAHF [Figure [Figure22A].
We hypothesized that Cyclin D1 expression may be inducing p53 through activation of the DNA damage response (DDR), as reported for Ras-induced senescence (reviewed in ). Indeed, we found nuclear accumulation of phosphorylated histone H2AX (pH2AX) at P10, concomitant with p53 activation [Figure [Figure2B,2B, B,2C].2C]. In addition, Chk1 was phosphorylated concomitantly with phosphorylation of p53, further indicating that the DDR pathway was active in the transgenic pineal gland at this time, but not at later time-points [Figure [Figure2D].2D]. These findings reveal that deregulated Cyclin D1 enhances the DDR pathway and activates p53 while cells are proliferating, but ongoing DDR and active p53 are not needed after cells have undergone senescence.
We next assessed whether reactive oxygen species (ROS) may be contributing to Cyclin D1-induced senescence in pineal cells, based on their role in Ras-induced senescence in cultured fibroblasts [23-25]. Using DCF-DA assay in explanted pineal cells, we found that ROS were indeed induced in response to Cyclin D1 expression, but not in wild-type pineal cells grown in the same conditions [Figure [Figure3A].3A]. We investigated whether ROS were responsible for activation of the DNA damage response in this setting. Indeed, Cyclin D1-induced ROS resulted in DNA damage foci marked by pH2AX, as well as the ROS-induced incorporation of oxidized dNTP, 8-Oxo-dGTP, into DNA Additional file 1: Figure S1D]. It also led to phosphorylation of Chk1, a component of the DNA damage response pathway [Figure [Figure3,3, left panel], and to increased expression of two p53 pathway effector proteins, 14-3-3 and p21 [Figure [Figure3B,3B, middle and right panels]. Treating cells with the ROS scavenger N-Acetyl Cysteine (NAC) resulted in abrogation of DNA damage Additional file 1: Figure S1D], abrogation of DDR activation, and absence of p53 pathway activation [Figure [Figure3B],3B], as well as evasion of senescence [Figure [Figure3C].3C]. By staining for 4-hydroxy-nonenal (HNE), a marker of lipid oxidation, we found evidence of oxidative stress in pineal sections of Irbp-Cyclin D1 mice, but not wild-type mice [Figure [Figure3D],3D], and there was also increased expression of the mitochondrial superoxide dismutase protein MnSOD [Figure [Figure3E],3E], which is induced by ROS stress in vivo . Thus, from the above in vitro and in vivo evidence, we conclude that Cyclin D1 expression results in accumulation of ROS, which in turn leads to activation of the DDR and the p53 pathway, resulting in induction of senescence.
RB pathway activation occurs after cell cycle exit and is associated with SAHF: To evaluate when the Rb pathway was engaged, we used western blotting to investigate the Cdk-dependent phosphorylation of Rb in pineal cell lysates. We investigated the status of Rb phosphorylation at Cdk4-dependent sites such as Ser790, and at Cdk2-dependent sites such as Ser612 [Figure [Figure4A].4A]. We found that Rb was phosphorylated at Cdk2-dependent sites (Ser612) at P10, when cells were proliferating, but decreased after cells exited the cell cycle by P24 [Figure [Figure4A].4A]. In contrast, Rb was phosphorylated at Cdk4-dependent sites (Ser790) from P10 through P35, even though most cells had ceased to proliferate by P24 [Figure [Figure4A].4A]. Rb phosphorylation at Cdk4-dependent sites was reversed at P49 as SAHF formed [Figure [Figure44A].
To understand the mechanism of Rb activation, we investigated the expression of the Cdk-inhibitors p16Ink4a, p15Ink4b, p18Ink4c, and p27Kip1 [27-30]. There was increased expression of p18Ink4c at all time points [Figure [Figure3B],3B], an increase in p15Ink4b expression at P49 [see Figure Figure1D,1D, but no changes in expression of p16Ink4a and p27Kip1 (not shown). We also evaluated the expression of Cdk4 and Cdk2, especially since Cdk2 inhibition was recently found to be important for Myc-induced senescence . We observed a modest decrease in Cdk4 expression from P10 through P49 [Figure [Figure3B],3B], but interestingly we found that Cdk2 expression was markedly reduced from P10 to P24 [Figure [Figure3B],3B], coincident with the timing of cell proliferation arrest and loss of Rb phosphorylation at Cdk2-specific sites. We conclude that Cdk2 repression correlates most closely with the initial proliferation arrest; and that diminished Cdk4-dependent Rb phosphorylation occurs at a later time-point and correlates with formation of SAHF.
p18Ink4closs delays p53-dependent cell cycle exit: Because of the observed increase in expression of p18Ink4c, we used a genetic approach to evaluate its role in Cyclin D1-induced senescence. In contrast to what occurs without p53 – where cell proliferation only slightly decreases from P10 to P35 and then increases as invasive tumor progresses [Figure [Figure4C,4C, top panel; and ], proliferation decreased from P10 through P49 without p18Ink4c [Figure [Figure4C,4C, bottom panel], but exceeded that in the Irbp-Cyclin D1 cells [Figure [Figure4C,4C, bottom panel, compare with Figure Figure11B].
Notably, p53 activation measured by phosphorylation at Ser15/20, and expression of the p53-target p21Cip1, persisted until P24 in Irbp-Cyclin D1, p18Ink4c -/- cells [Figure [Figure4D],4D], correlating with the prolonged cellular proliferation. Further, Cdk2 expression persisted until P24 in Irbp-Cyclin D1, p18Ink4c -/- cells [Figure [Figure4].4]. These findings indicate that p18Ink4c loss delayed but did not prevent p53-dependent events leading to cell cycle exit.
Interestingly, loss of Cdk4-dependent Rb phosphorylation still occurred in the absence of p18Ink4c, again correlating with the appearance of SAHF [Figure [Figure4D].4D]. In fact, the majority of Irbp-Cyclin D1, p18Ink4c -/- cells displayed SAHF by P49 Additional file 2: Figure S2A], whereas SAHF never formed in Irbp-Cyclin D1, p53 -/- cells . In addition to SAHF, the senescence markers Dec1 and DcR2 were also expressed in Irbp-Cyclin D1, p18Ink4c -/- cells at P49 Additional file 1: Figure S2B]. Findings were similar in vitro using pineal cells explanted from P10 animals and cultivated for 10-20days: Explanted Irbp-Cyclin D1 cells showed evidence of senescence, including loss of proliferation (measured by BrdU incorporation), and positive staining for SABG, by 10days in culture Additional file 1: Figure S1B, 1C], while the Irbp-Cyclin D1, p53 -/- cells continued to proliferate and did not senesce Additional file 1: Figure S1B, bottom]. In contrast, the Irbp-Cyclin D1, p18Ink4c -/- cells did show evidence of senescence, but it was delayed until close to 20days in culture Additional file 2: Figure S2C]. We conclude that p18Ink4c slowed proliferation but was not essential for most Cyclin D1 expressing cells to cease proliferating and become senescent.
p53 and p18Ink4cact independently in suppressing Cyclin D1-driven tumors: The persistence of a small number of proliferating cells by P49, in Irbp-Cyclin D1, p18Ink4c -/- mice, was important because it led to pineoblastoma by 7-10months of age in all mice examined (n=15). Examining mice at 3-5months of age, we observed an obvious border between the malignant and pre-malignant parts of the pineal gland [Figure [Figure5A,5A, left]; this border disappeared as the tumor infiltrated the whole pineal gland [Figure [Figure5A,5A, right], and SAHF were lost in the emerging Irbp-Cyclin D1, p18Ink4c -/- tumor [Figure [Figure5B].5B]. Dual immunostaining for BrdU and SAHF clearly demonstrated that proliferating pinealocytes were distinct from those that displayed SAHF [Figure [Figure55C].
We considered whether the prolonged proliferation in the absence of p18Ink4c might have derailed a p53-dependent arrest in the malignant tumors. Western blotting showed that Irbp-Cyclin D1, p18Ink4c -/- tumors still expressed the p53 protein [Figure [Figure5D],5D], and sequencing of p53 exons 5-8 did not reveal mutations in genomic DNA from nine different Irbp-Cyclin D1, p18Ink4c -/- pineal tumors (data not shown). Further, using primary cultures of pineal tumor cells, we found that both gamma irradiation and treatment with etoposide resulted in increased p53 phosphorylation and in p53-dependent increases in p21Cip1 and 14-3-3 in Irbp-Cyclin D1, p18Ink4c -/- but not Irbp-Cyclin D1, p53 -/- tumor cells [Figure [Figure5E].5E]. These findings confirmed that p53 remained intact in Irbp-Cyclin D1, p18Ink4c -/- tumor cells. In contrast, there was decreased p18Ink4c expression in Irbp-Cyclin D1, p53-/- tumors, suggesting that p18Ink4c may act as a tumor suppressor, even in a p53-null setting [Figure [Figure5D,5D, D,5F].5F]. However, preliminary results show no enhanced tumor susceptibility in Irbp-Cyclin D1, p53-/-, p18Ink4c -/- (double knock-out) animals (data not shown).
Cdk2 is induced in bothp18Ink4c -/-andp53 -/-tumors, and may be a suitable therapeutic target: Several changes in Cdk2 expression suggested that it may represent a critical effector of Cyclin D1-driven tumorigenesis. In the Irbp-Cyclin D1, and Irbp-Cyclin D1, p18Ink4c -/- animals, Cdk2 was repressed as cells ceased to proliferate, and repression was markedly blunted in the Irbp-Cyclin D1, p53 -/- pineal gland [Figure [Figure5F,5F, compare with Figure Figure4D],4D], in which neither cell cycle arrest nor senescence was observed [see Figure Figure4A].4A]. Repression of Cdk2 seemed specific because there was no repression of another closely related cell cycle protein, Cdk1 [Additional file 2: Figure S2D]. Lastly, Cdk2 increased in tumors progressing from the largely senescent, Irbp-Cyclin D1, p18Ink4c -/- pineal gland [Figure [Figure6A],6A], and Cdk2 expression correlated with Ki67-positivity in emerging tumors [Figure [Figure6B].6B]. Areas in the Irbp-Cyclin D1, p18Ink4c -/- tumors that remained Ki67-negative displayed little Cdk2 [Figure [Figure6B6B and and66C].
To address the role of Cdk2 repression as a possible therapeutic target, we treated explanted Irbp-Cyclin D1, p18Ink4c -/- and Irbp-Cyclin D1, p53 -/- pineal tumor cells with the Cdk2-inhibitor CVT313, at a concentration of 5μM, known to specifically inhibit Cdk2 [11,31]. CVT313 treatment decreased cell number (estimated by total cellular area) in Irbp-Cyclin D1, p18Ink4c -/- and Irbp-Cyclin D1, p53 -/- tumor cells in 8-well chamber slides [Figure [Figure6D,6D, upper panel]. Furthermore, CVT313-treated cells showed an increase in positive staining for SABG activity [Figure [Figure6D,6D, lower panel, and Figure Figure6E].6E]. Importantly, treatment of pre-tumorigenic Irbp-Cyclin D1 pineal cells with CVT313 also decreased the apparent cell number [Figure [Figure6E],6E], while treatment of wild-type pineal cells did not seem to have a noticeable effect, either on cellularity or SABG positivity [Figure [Figure66E].
We assessed whether Cdk2 inhibition by CVT313 was primarily affecting cellular proliferation by BrdU incorporation assay. Indeed, we found that CVT313 treatment decreased proliferation in oncogene-expressing and pre-tumorigenic cells, but not in wild-type pineal cells [Figure [Figure7A,7A, quantitation in Figure Figure7B].7B]. There was no evidence of any increase in apoptotic cells after CVT313 treatment in either cell type, as measured by TUNEL staining (negative data not shown).
To investigate whether the effects on senescence induction were specific to Cdk2 inhibition, we treated explanted Irbp-Cyclin D1, p53-/- and Irbp-Cyclin D1, p18Ink4c-/- cells with a specific Cdk4-inhibitor, NSC 625987 [32,33]. Inhibition of Cdk4 decreased proliferation (measured by BrdU incorporation), though to a lesser extent than seen with Cdk2 inhibition [Figure [Figure7C].7C]. However, unlike Cdk2 inhibition, it did not result in any detectable increase in SABG staining [Figure [Figure7D].7D]. This demonstrates that Cdk2 inhibition was specifically relevant to induction of senescence in Cyclin D1-expressing pineal cells.
Emerging evidence supports the concept that cellular senescence represents a likely mechanism through which oncogenic transformation is suppressed. Senescence has been observed in pre-malignant lesions in mouse and in man, but not in fully transformed counterparts of these lesions (reviewed in [21,34]). Because of the time lag in progression of premalignant lesions and the incomplete penetrance, it has been assumed that accumulation of as yet poorly-defined genetic or epigenetic changes likely contribute to the emergence of a tumor from a premalignant, apparently senescent lesion.
Our work provides new insight into cellular and molecular events that occur as oncogene-expressing cells arrest, become senescent, and finally emerge or escape from the senescent state as a malignant tumor. This is the first in vivo description of temporal morphologic and molecular events accompanying the evolution of an oncogene-driven senescent state, showing a previously unrecognized temporal sequence where cell cycle exit preceded formation of heterochromatin foci by several weeks.
Two tumor suppressor genes, p53 and p18Ink4c, played distinct roles during this process. P53 activation occurred concomitantly with an active DNA damage response, and was essential to drive cell cycle exit, temporally associated with Cdk2 repression and loss of Cdk2-dependent phosphorylation of the retinoblastoma protein Rb. Days later, reversal of Cdk4-dependent phosphorylation of the Rb protein correlated with the emergence of morphological and biochemical changes of oncogene-induced senescence. At that point, though, there was no evidence of p53 pathway activation. This is the first direct in vivo evidence for distinct temporal roles for these two tumor suppressors in the senescence process.
The early and transient activation of the p53 pathway suggested that p53 was integral for the initial cell cycle exit but not directly involved in formation of SAHF. Other models have also shown conflicting and context-dependent evidence for the role of p53 in the formation of SAHF [35-37]. In contrast, Rb activation was delayed and stable. Rb seemed to be important in both cell cycle exit as well as formation of SAHF: compromise of the Rb pathway through loss of p18Ink4c (the major known function of which is inhibition of Cdk4/6 to indirectly activate Rb [38-40]) led to a delay in initial cell cycle exit, and eventually to complete penetrance of tumor progression within the senescent-like lesion. Taken together, these findings implicate Rb, rather than p53, as the key protein needed to foster the emergence and maintenance of SAHF, thought to be responsible for repression of cell-cycle genes [3,35]. Involvement of Rb in the formation of SAHF has been shown in other settings: human RB was shown to directly co-localize with SAHF [35,36], and inactivation of the p16INK4a/RB pathway impairs formation of RasG12V-induced SAHF in human fibroblasts . In our model, p53-driven cell cycle exit correlated with hypo-phosphorylation of Rb at Cdk2-dependent sites, while formation of SAHF correlated with hypo-phosphorylation at Cdk4-dependent sites. This suggests that hypo-phosphorylation of these specific residues may be involved in SAHF formation. It will be interesting to evaluate whether mutated forms of Rb that cannot be phosphorylated at these particular Cdk4 sites can more robustly foster the appearance of SAHF.
Our results suggest that p53 and p18Ink4c represent separate tumor suppressor pathways in Cyclin D1-driven pineoblastoma. While tumors progressed within 3-4months in p53 -/- animals, they appeared much later, after 7-10months in p18Ink4c -/- mice. Also, the p53 pathway was intact in p18Ink4c -/- tumors, further proving that the two pathways of tumor suppression are distinct. Tumor suppression required functional p53 and p18Ink4c, as neither was sufficient to prevent tumor progression alone. While the cell cycle exit after P10 was clearly p53-dependent, absence of p18Ink4c delayed the cell cycle exit but did not prevent it in the majority of cells, which went on to express other markers of senescence. However, few cells continued to proliferate, resulting in tumorigenesis. It thus appears that, while p53 loss resulted in abrogation of cell cycle exit altogether, loss of p18Ink4c decreased the threshold for bypass of the p53-dependent cell cycle exit in a subset of cells.
In our model, p53-dependent cell cycle arrest was associated with marked Cdk2 repression, while Cdk2 levels were maintained in Irbp-Cyclin D1, p53 -/- cells which never exited the cell cycle [see Figure Figure5F.5F. While a role for Cdk2 repression in facilitating senescence has been shown in an earlier report , ours is the first description of Cdk2 repression occurring in a temporal association with p53-dependent cell cycle exit. This indicates that Cdk2 repression might be a novel p53-dependent mechanism to foster cell cycle exit, especially since no similar changes were seen in the related cell cycle regulator Cdk1. However, additional work will be needed to investigate whether Cdk2 repression is a direct p53-dependent effect, and whether it is sufficient to induce cell cycle exit and induction of senescence. Moreover, since Cdk2 and other Cdks are also regulated post-transcriptionally by phosphorylation and by their binding to CDK-inhibitors, future work should focus on elucidating these molecular aspects for complete mechanistic understanding of the role of Cdk2 and other Cdks in inducing senescence. Future studies utilizing the established in vitro model, as well as genetically engineered mouse models, should be able to specifically dissect the role of Cdk2 in tumor progression, and upstream and downstream mechanisms leading to its repression and to cell cycle exit.
Finally, although tumors arising in a p53 -/- setting were molecularly different from those arising in a p18Ink4c -/- setting, Cdk2 levels were high in both (compared to senescent cells) and both cell types responded to Cdk2 inhibition. While Cdk4 inhibition also decreased cell proliferation, only Cdk2 inhibition resulted in features of senescence in treated cells. These conclusions are based on the published specificity of the inhibitors used at the corresponding concentrations. Ideally, we would have preferred to document inhibitor-induced pRb specific phosphorylations and specific kinase activity in each experiment, however the low number of primary cells used in these experiments was prohibitive.
Keeping the above limitations in mind, these findings provide a rationale for exploring the use of pharmacological Cdk inhibition, specifically Cdk2, to induce senescence in tumor cells, irrespective of whether the p53 pathway is compromised. Such an approach to therapy may be especially useful in tumors where the primary insult lies with deregulated Cyclin D1 expression, as in the reported model.
Irbp-Cyclin D1 transgenic mice  were bred with p53 -/- (Jackson Laboratory, Maine), or p18Ink4c -/- mice  and maintained in a mixed C57BL/6×129/Sv genetic background. PCR for targeted alleles was used to verify mouse genotypes as described [41,42]. Animals were euthanized at defined time points or when obviously ill in accordance with the American University of Beirut (AUB) Institutional Animal Care and Use Committee guidelines; all studies were approved by this committee.
Protein lysates were prepared from pineal tissue by lysis in Universal Lysis Buffer. Electrophoresis was performed using 8, 10, or 12% Tris-Chloride gels, transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules, CA), and detected using antibodies to p21Cip1, Cdk4, Cdk2, Cdk1, Hsc70, phospho-S790 Rb, total and phospho-specific p53 at Ser15/20 (Santa Cruz Biotechnology, Santa Cruz, CA); phospho-S612 Rb (MBL International, Woburn, MA); p18Ink4c (Zymed, San Francisco, CA); human Cyclin D1 (BD-Pharmingen, San Diego, CA); hemagglutinin (HA) epitope (Covance, Trenton, NJ); and 14-3-3 (Abcam, Cambridge, UK).
For evaluation of p53 pathway, pineal tumors were excised, dispersed, and plated onto permanox chamber slides, and grown in culture in 10% FBS in DMEM for 72hours, then treated with 6Gy irradiation at 1Gy/min, or 10μM Etoposide. Cells were collected 24hours after irradiation, or 6hours after Etoposide treatment, and protein extraction and western blotting was performed as above.
Brain tissue was fixed in 4% paraformaldehyde for 72hours then embedded in paraffin. For mice older than 10days, skulls were peeled off before embedding. For BrdU incorporation, 49day-old mice were treated with intraperitoneal injection of 50mg/Kg of BrdU (Sigma-Aldrich, St Louis, MO), every 2hours×5, then sacrificed 2hours later. 4-8μm sections were cut from paraffin-embedded tissues and deparaffinized. Antigen retrieval was performed in a microwave at high power for 5 minutes, followed by low power for 5 minutes x2 in citrate antigen retrieval buffer (pH 6.0). Slides were incubated with anti-Ki67 (NovoCastra, Newcastle, UK), anti-pH2AX (Cell Signaling Technology, Danvers, MA), anti-Dec1, anti-DcR2, anti-MnSOD, anti-p15Ink4b, or anti-Cdk2 antibodies(Santa Cruz Biotechnology), followed by biotinylated secondary antibody; and detected using streptavidin conjugated to horseradish peroxidase and DAB substrate (DAKO, Carpinteria, CA). For immunofluorescence staining, anti-H3K9me3 (Upstate Laboratories, Syracuse, NY), anti-4HNE (Alpha Diagnostic, San Antonio, TX, USA), anti-BrdU, anti-p21 (Santa Cruz Biotechnology), anti-phosphorylated Chk1 at Ser345 (Cell Signaling Technology), anti-14-3-3, and anti-8(OH)dG (Abcam, Cambridge, UK) antibodies were detected with Cyanine 2, Cyanine 3, or Alexafluor488 secondary antibodies. The number of Ki67 positive cells, pH2AX positive cells, and BrdU-positive cells was manually counted from 5-7 representative fields, at 200x magnification, and normalized to total cell number. Digital photomicrographs were obtained using a Zeiss 510 NLO multiphoton/ confocal laser scanning microscope. Composite images were constructed using Photoshop CS4 software (Adobe Systems, Mountain View, CA).
Pineal cells were explanted at postnatal day 10 (P10); tumors were explanted when clinically apparent (bulging cranium). Cells were plated onto 8-well permanox chamber slides (Nunc, Rochester, NY), and cultured in DMEM with 10%FBS, 1% glutamine, and 1% Pen/Strep.
To measure intracellular ROS in vitro, cells were treated with a peroxide sensitive reagent CM-H2DCF-DA (CM-H2DCF-DA; Molecular Probes, Eugene, OR) at 10μM for 20min at 37°C and observed under a fluorescence microscope.
Explanted pineal cells were treated with N-Acetyl Cysteine (Sigma Aldrich) at a concentration of 5mM. Media was renewed daily. Cells were treated for 10days, and stained for SABG as described . For DDR pathway analysis, cells were fixed and stained after 4days.
Explanted cells were treated with CVT313 at 5μM (Santa Cruz Biotechnology), NSC625987 at 1μM (Tocris Bioscience, Ellisville, MO, USA), or DMSO vehicle; media was renewed every 3days. Cells were fixed and stained for SABG after 7days, and counterstained with eosin. For quantification of proportion of cells positive for SABG, 10 random fields were selected, and digital photomicrographs were analyzed using Adobe Photoshop CS4 software, by color selection and area analysis. For quantification of cellular accumulation, all the area of the well was photographed over 12 fields. Digital photomicrographs were analyzed using Adobe Photoshop CS4 software, by area selection tool. For BrdU incorporation assay, cells were treated with BrdU at a concentration of 33μM for 2hours, fixed with 50%methanol/50%acetone solution for 2 minutes, then processed as detailed above.
The authors declare that they have no competing interests in relation to the work described.
HZ carried out the most of the cellular and molecular studies, and participated in drafting the manuscript. MH, LM, and NEC performed immunohistochemical studies, mouse genotyping for the reported experiments, and helped in drafting the manuscript. GD and SXS participated in the design of the study and reviewed the manuscript. RS conceived the study, and participated in its design and coordination and drafted the manuscript. All authors read and approved the final manuscript.
Figure S1: A) High-magnification images of senescence-associated heterochromatin foci (SAHF) marked by H3K9me3, in Irbp-Cyclin D1 (D1) versus wild-type (WT) pineal cells at P49. B) Senescence-associated beta galatosidase (SABG) staining of cultured pineal cells explanted from wild-type (WT), Irbp-Cyclin D1 (D1), and Irbp-Cyclin D1, p53 -/- (D1p53-/-) animals, as indicated. SABG staining was done after 10 days of culture. C) Top panel: BrdU-incorporation and immunofluorescence staining of wild-type (WT) and Irbp-Cyclin D1 (D1) pineal cells, as indicated, after 10 days in culture. Bottom panel: corresponding DAPI-stained nuclei. D) Right panels: Immunofluorescence staining for 8(OH)dG and pH2AX, in wild-type (WT), Irbp-Cyclin D1 (D1), and NAC-treated Irbp-Cyclin D1 explanted pineal cells, as indicated. Left panels: corresponding DAPI staining of nuclei.
Figure S2: A) Representative immunohistochemical staining for Ki67 (left) and immunoflourescence for H3K9me3 (right) and corresponding DAPI (middle) staining of Irbp-Cyclin D1, p18Ink4c-/- pineal sections at the indicated ages. B) Immunostaining for Dec1 and DcR2, in Irbp-Cyclin D1, p18Ink4c-/- pineal glands at the indicated ages. C) SABG staining of cultured Irbp-Cyclin D1, p18Ink4c -/- pineal cells after 14 and 20 days in culture, as indicated. D) Western blotting for the indicated proteins in pineal glands of the indicated genotypes, at the indicated ages.
This work was supported by an MPP grant from the American University of Beirut, and in part by the American Lebanese Syrian Associated Charities (ALSAC) and International Outreach Program at St Jude Children’s Research Hospital, Memphis, TN. The authors thank Bristol-Myers Squibb, M. Barbacid, and M. F. Roussel for donating the p18Ink4c -/- mice; and support from the AUB Core Laboratory Shared Resources.